Evidence map›Paper›PMID 33144066›Full record

ReviewExperimental neurology2021

Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.

Surojit Paul, Eduardo Candelario-Jalil

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Experimental neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 386 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
386citing papers in PubMed, 7 pooled it
28.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

386 citing papers in PubMed, 7 syntheses or guidelines pooled it, 728 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Review
  10. Review
  11. Article
  12. Article
  13. Overestimation of ischemic core on baseline MRI in acute stroke.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2026
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

326 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Surojit PaulDepartment of Neurology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA. Electronic address: spaul@salud.unm.edu.
Eduardo Candelario-JalilDepartment of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA.
University of Florida · USUniversity of New Mexico · US

Funding

Role of Brain Specific Tyrosne Phosphatase STEP in Neuroprotection and DeathR01NS059962 · NINDS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PAUL, SUROJIT · 2008 to 2023
$5.9M
Multi-pronged Approach to Recalibrating the Inflammatory Cascade in Ischemic Stroke with BET blockadeR01NS109816 · NINDS · UNIVERSITY OF FLORIDA · PI CANDELARIO-JALIL, EDUARDO JESUS · 2019 to 2023
$1.9M
Neurovascular Protection by Adropin in Ischemic StrokeR01NS103094 · NINDS · UNIVERSITY OF FLORIDA · PI CANDELARIO-JALIL, EDUARDO JESUS · 2018 to 2021
$1.5M
NINDS NIH HHS R01 NS059962NINDS NIH HHS R01 NS103094NINDS NIH HHS R01 NS109816
6 · The paper itself

Abstract

Stroke is the leading cause of disability and thesecond leading cause of death worldwide. With the global population aged 65 and over growing faster than all other age groups, the incidence of stroke is also increasing. In addition, there is a shift in the overall stroke burden towards younger age groups, particularly in low and middle-income countries. Stroke in most cases is caused due to an abrupt blockage of an artery (ischemic stroke), but in some instances stroke may be caused due to bleeding into brain tissue when a blood vessel ruptures (hemorrhagic stroke). Although treatment options for stroke are still limited, with the advancement in recanalization therapy using both pharmacological and mechanical thrombolysis some progress has been made in helping patients recover from ischemic stroke. However, there is still a substantial need for the development of therapeutic agents for neuroprotection in acute ischemic stroke to protect the brain from damage prior to and during recanalization, extend the therapeutic time window for intervention and further improve functional outcome. The current review has assessed the past challenges in developing neuroprotective strategies, evaluated the recent advances in clinical trials, discussed the recent initiative by the National Institute of Neurological Disorders and Stroke in USA for the search of novel neuroprotectants (Stroke Preclinical Assessment Network, SPAN) and identified emerging neuroprotectants being currently evaluated in preclinical studies. The underlying molecular mechanism of each of the neuroprotective strategies have also been summarized, which could assist in the development of future strategies for combinational therapy in stroke treatment.

Indexed as

NeuroprotectionAnimalsClinical Trials as TopicHumansIschemic StrokeNeuroprotective AgentsNeuroprotective AgentsBlood-brain barrier dysfunctionClinical trialsComorbiditiesExcitotoxicityIschemic strokeNeuroinflammationNeuroprotectionNeuroprotective agentsOxidative stressPreclinical studies

Identifiers

PMID33144066
PMCPMC7869696
OpenAlexW3097256238

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.